Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 20, 2011 - Issue 1
Submit an article Journal homepage
298
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin

Adam J Foley-Comer Roche Centre for Applied Clinical Development, Welwyn Garden City, UK; Bioline Rx. Ltd, Jerusalem, Israel
,
Anne-Marie Young Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK +44 0 1707 365728; +44 0 1707 383149; [email protected]
,
Fiona Russell-Yarde Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK +44 0 1707 365728; +44 0 1707 383149; [email protected]
&
Paul Jordan F Hoffmann-La Roche AG, Basel, Switzerland
Pages 3-12 | Published online: 29 Nov 2010

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Lisa M Younk, Lisa Uhl & Stephen N Davis. (2011) Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opinion on Drug Metabolism & Toxicology 7:6, pages 753-763.
Read now

Articles from other publishers (4)

Raju Kanukula, Abdul Salam, Anthony Rodgers & Bishoy Kamel. (2021) Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. Clinical Pharmacokinetics 60:2, pages 165-175.
Crossref
Aimei Liu, Qinghua Wu, Jingchao Guo, Irma Ares, José-Luis Rodríguez, María-Rosa Martínez-Larrañaga, Zonghui Yuan, Arturo Anadón, Xu Wang & María-Aránzazu Martínez. (2019) Statins: Adverse reactions, oxidative stress and metabolic interactions. Pharmacology & Therapeutics 195, pages 54-84.
Crossref
Marika Massaro, Egeria Scoditti, Mariangela Pellegrino, Maria Annunziata Carluccio, Nadia Calabriso, Martin Wabitsch, Carlo Storelli, Matthew Wright & Raffaele De Caterina. (2016) Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes. Pharmacological Research 107, pages 125-136.
Crossref
Francisco A. Monsalve, Radha D. Pyarasani, Fernando Delgado-Lopez & Rodrigo Moore-Carrasco. (2013) Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases. Mediators of Inflammation 2013, pages 1-18.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.